Conaire Quinn (38) from Ballynahinch is eligible for a groundbreaking new Motor Neuron Disease treatment, but is being denied ...

KLTO‑202 is an experimental gene therapy that would deliver the instructions for a protein that may reduce inflammation and ...

A noninvasive therapy delivering gentle spinal stimulation was shown to slow disease progression and extend survival in an ...

A team of neuroscientists in Australia has found that restoring copper levels in the brain dramatically reduced Parkinson-like damage in mice. The approach restored a protein’s function, and the same ...

The findings of two recent studies give hope that the disease could one day be reversed in humans—but experts warn that this ...

Groundbreaking research by Sydney University found a new brain protein involved in Parkinson’s disease and a way to modify it ...

Scientists at the University of Sydney have uncovered a malfunctioning version of the SOD1 protein that clumps inside brain ...

Ms Siti Nur Sabrina Anis, 26, had to swop one set of wheels for another – her Yamaha motorcycle for a motorised wheelchair.

Eight years after receiving a life-shattering diagnosis, a New Jersey mother credits an “amazing” new drug for stopping her disease in its tracks.

Raziel Green, 52, an active runner and mother of two, was diagnosed with a rare form of ALS in 2017. Since starting a clinical trial nearly eight years ago, her symptoms have not gotten any worse.

The decision on the SOD1 ALS program does not impact Voyager’s other gene therapy programs; the Company continues to expect IND filings in 2025 from Neurocrine Biosciences for the program in ...